Skandinaviska Enskilda Banken AB publ has reduced its stake in Regeneron Pharmaceuticals, Inc. by 16.4% in the third quarter, now owning 56,974 shares valued at $32.01 million. Other institutional investors have also adjusted their positions in REGN. Several Wall Street analysts have updated their price targets and ratings for Regeneron, with a consensus “Moderate Buy” rating and an average target price of $793.81.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Skandinaviska Enskilda Banken AB publ Lowers Stock Position in Regeneron Pharmaceuticals, Inc. $REGN
Skandinaviska Enskilda Banken AB publ has reduced its stake in Regeneron Pharmaceuticals, Inc. by 16.4% in the third quarter, now owning 56,974 shares valued at $32.01 million. Other institutional investors have also adjusted their positions in REGN. Several Wall Street analysts have updated their price targets and ratings for Regeneron, with a consensus “Moderate Buy” rating and an average target price of $793.81.